Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VV169 in Relapsed or Refractory Multiple Myeloma
NCT07802717Phase 1Recruiting
- Sponsor
- Vyriad
- Start
- Sep 2026
- Primary completion
- Aug 2027
- Countries
- 1
01
Overview
Phase 1, open-label trial of VV169 in multiple myeloma (MM) (2 arms), sponsored by Vyriad. Primary endpoints: Maximum Tolerated Dose at 2 years and Recommended Phase 2 Dose at 28 days. Started Sep 2026; status: recruiting.
02
Drugs
VV169
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT07802717.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07802717.